WHO ICTRP trial
A study of the effectiveness and safety of gantenerumab in participants at risk…
ISRCTN54460428 · International Standard Randomised Controlled Trial Number (ISRCTN) · Not Recruiting
Key facts
| Trial ID | ISRCTN54460428 |
|---|---|
| Public title | A study of the effectiveness and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer's disease |
| Scientific title | A Phase III, multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of gantenerumab in participants at risk for or at the earliest stages of Alzheimer's disease |
| Primary sponsor | Roche (Switzerland) |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase III |
| Countries | Argentina;Australia;Belgium;Canada;England;France;Germany;Ireland;Italy;Japan;Netherlands;New Zealand;Poland;Russian Federation;Scotland;Spain;Sweden;United Kingdom |
| Conditions | Alzheimer's disease Nervous System Diseases Alzheimer disease |
| Interventions | Participants will have an equal chance of being placed in the gantenerumab or placebo treatment groups. Study treatment will be given by injection. There will be an initial 9-month dose escalation, where participants will receive increasing… |
| Registration date | Apr 25, 2022 |
| Target size | 1200 |
| Secondary IDs | 2021-001184-25;NCT05256134;WN42444, IRAS 1004248, CPMS 50781 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: